IceCure Medical Ltd. (Nasdaq: ICCM) experienced a dramatic surge in its stock price on Wednesday, closing at $6.40 after a 200.47% rally. The significant move came on the heels of two key announcements: a substantial increase in the U.S. commercial install base for its ProSense cryoablation system and a $5.5 million private placement. Pre-market trading on Thursday indicated continued volatility, with shares changing hands at $7.27 as of 6:59 a.m. EDT.
Commercial Progress and Financing Details
In a commercial update, IceCure reported that its active U.S. install base for ProSense, which is used in breast cancer cryoablation, jumped 70% since receiving FDA marketing clearance in October 2025. The company noted that the procedure has now been performed in major cities including Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, and Memphis. Chief Executive Eyal Shamir described this as the "early stages of a significant commercial opportunity" in the U.S. breast cancer cryoablation market, emphasizing the importance of physician training and patient access.
Separately, IceCure announced a private placement agreement with a single healthcare-focused institutional investor. The company will issue 1,833,334 ordinary shares, along with Series D and Series E warrants, at a combined price of $3.00 per share. The gross proceeds are expected to be approximately $5.5 million before fees, with the closing scheduled for or around June 18, 2026. The funds will be used for working capital and general corporate purposes. The Series D warrants have a five-year term, while the Series E warrants expire after one year, both with an exercise price of $3.00.
Market Implications and Competitive Landscape
The news has created a mixed picture for investors. On one hand, the rapid adoption of ProSense suggests strong market acceptance for the company's less-invasive treatment option, which uses freezing to destroy cancerous tissue. This could position IceCure favorably against larger competitors like Boston Scientific (with its ICEfx system) and Varian/Siemens Healthineers (CryoCare Touch). However, the fresh equity and potential dilution from the new shares and warrants could cap further upside. The company is also seeking shareholder and Nasdaq approval to lower the exercise price of certain March 2026 warrants from $16.50 to $3.00, which would add further share supply if exercised.
IceCure's ProSense system is FDA-cleared for the local treatment of low-risk breast cancer in women aged 70 and older who are receiving adjuvant endocrine therapy, including those who are not candidates for surgery. The company faces both commercial and regulatory challenges, and it has flagged risks related to sales execution, funding, intellectual property, and instability in Israel and the Middle East.
Nasdaq will be closed on Friday, June 19, in observance of Juneteenth, which may add to near-term trading uncertainty. The regular trading session opens at 9:30 a.m. EDT, with pre-market activity from 4 a.m. to 9:30 a.m. often seeing thinner liquidity and higher volatility.
